SOLICITATION NOTICE
B -- Evaluation of Autoantibody Profiles
- Notice Date
- 8/10/2010
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100178-KM
- Archive Date
- 9/9/2010
- Point of Contact
- Karri L. Mares, Phone: 3014357774, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
maresk@mail.nih.gov, cr214i@nih.gov
(maresk@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852, UNITED STATES Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG) plans to procure on a sole source basis an evaluation of autoantibody profiles through multiplex proteomic array technologies from Arizona State University, Centerfor Personal Diagnostics, The Biodesign Institute, 1001 S. McAllister Avenue, Tempe,77115287-6401. The supplies-and services herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106 (b)(1). The North American Industry Classification System code 621511 and the business size standard is $13.5 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance shall be for twelve (12) months from date of award. P53 mutations are prevalent among ER- breast cancers and likely are instrumental in their development and aggressiveness. Investigators at Arizona State University have developed unique technologies to identify tumor antigens in serum or plasma. Of the known tumor antigens that induce detectable antibodies known as autoantibodies, in early cancer, mutated p53 protein was the first identified and the most studied. There is now evidence that there are many other potential tumor antigens that elicit an immune response and can give rise to autoantibodies. The proteomic technologies that have been developed at Arizona State University allow for the screening of relevant autoantibodies that subsequently can be used to develop more specific assays with high throughput. The contractor shall determine the association of a spectrum of autoantibody profiles and those with breast cancer risk among ER-negative breast cancer cases. The autoantibody profiles of 90 subjects will be evaluated. For those subjects identified, plasma or serum samples will be stored and evaluated through the mutiplex proteomic array technologies autoantibody profiles. Ten thousand proteins will be measured on array technologies to screen for autoantibodies that are associated with ER-negative disease. The contractor will generate quantitative data of proteomic autoantibody profiles and transfer autoantibody data from plasma samples. Arizona State University and the laboratories of Dr.’s Ji Qiu and Joshua Labaer are uniquely qualified to perform this work. AU has developed a unique proteomic platform for screening autoantibodies and has the sole expertise to carry out this work utilizing the 90 samples that will be provided by the NCI. The unique technology AU provides has strong advantages over other existing technologies: 1) screens over 10,000 proteins (from at least 7500 known genes) in one batch; 2) uses cDNA clones for in-vitro transcription and translation on the arrays, which avoids the need to express and then purify important proteomic targets and; 3) averts biases related to hydrophilicity / solubility of protein targets, which is limiting for other methods. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 11:00 AM EST, on August 25, 2010. For further information, please contact Karri Mares, Contract Specialist via electronic mail at maresk@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: NCI-100178-­KM on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100178-KM/listing.html)
- Record
- SN02235167-W 20100812/100810235624-84ea96e628a1d9967deda5bd8665ce89 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |